目的 觀察腎復(fù)康膠囊聯(lián)合貝那普利治療慢性腎小球腎炎的臨床療效。方法 選擇2013年1月—2014年12月就診于內(nèi)蒙古醫(yī)科大學(xué)附屬醫(yī)院的慢性腎小球腎炎患者78例,隨機分為治療組和對照組,每組各39例。對照組在常規(guī)治療的基礎(chǔ)上口服鹽酸貝那普利片10 mg/次,1次/d;治療組在對照組的基礎(chǔ)上加服腎復(fù)康膠囊,5粒/次,3次/d。4周為1個療程,兩組患者均治療3個療程。比較兩組的臨床療效,測定兩組患者治療前后24 h尿蛋白定量(24 h Pro)、尿紅細胞計數(shù)(RBC)、尿β2-微球蛋白(β2-MG)以及腎功能指標尿素氮(BUN)、血肌酐(Scr)和血脂四項三酰甘油(TG)、膽固醇(TC)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)。結(jié)果 治療后,治療組、對照組的總有效率分別為94.87%、84.62%,兩組總有效率比較差異有統(tǒng)計學(xué)意義(P < 0.05)。治療后兩組患者的24 hPro、RBC、β2-MG、BUN和Scr水平均較同組治療前顯著降低,同組治療前后比較差異有統(tǒng)計學(xué)意義(P < 0.05、0.01),且治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P < 0.05、0.01)。治療后兩組患者的TC、TG、LDL-C水平均較同組治療前顯著降低,但HDL-C水平明顯升高,同組治療前后比較差異有統(tǒng)計學(xué)意義(P < 0.05、0.01),且治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P < 0.05)。兩組患者治療期間均未出現(xiàn)嚴重不良反應(yīng)。結(jié)論 腎復(fù)康膠囊聯(lián)合貝那普利片治療慢性腎小球腎炎具有良好療效,在減少尿蛋白定量、尿紅細胞計數(shù),降低血肌酐、血尿素氮方面要優(yōu)于單用貝那普利片治療,且未見嚴重不良反應(yīng),值得臨床推廣應(yīng)用。

Objective To observe the clinical effect of Shenfukang Capsule combined with Benazepril Tablets in treatment of chronic glomerulonephritis. Methods Patients (78 cases) with chronic glomerulonephritis in the Affiliated Hospital of Inner Mongolia Medical University from January 2013 to December 2014 were randomly divided into control and treatment groups, and each group had 39 cases. The patients in the control group were po administered with Benazepril Tablets at the basis of conventional therapy, 10 mg/time, once daily. And the patients in the treatment group were po administered with Shenfukang Capsule at the basis of control group, 5 capsules/time, three times daily. One course of treatment was 4 weeks. Two groups were treated for three courses. The clinical efficacy of two groups was compared. The other index were determined, such as the changes of 24 h urine protein (24 h Pro), urine red blood cell count (RBC), β2 microglobulin (β2-MG), renal function index serum creatinine (Scr), blood urea nitrogen (BUN), and four items of blood lipid tests, including three triacylglycerol (TG), cholesterol (TC), low density lipoprotein (LDL), and high density lipoprotein (HDL) of the patients. Results After treatment, the efficacies in the control and treatment groups were 94.87% and 84.62%, respectively, and there were differences between two groups (P < 0.05). After treatment, the levels of 24 h Pro, RBC, β2-MG, BUN, and Scr levels in two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05, 0.01). And these indicators in treatment group improved better than those in the control group, with significant difference between two groups (P < 0.05, 0.01). After treatment, the levels of TC, TG, and LDL-C in two groups were significantly reduced, but the levels of HDL-C in two groups significantly increased, and the difference was statistically significant in the same group (P < 0.05, 0.01). And these indicators in treatment group improved better than those in the control group with significant difference between two groups (P < 0.05). After treatment, routine urine white blood cells and red blood cell count in two groups were significantly reduced, and index in the treatment group were obviously lower than those in the control group with significant difference between two groups (P < 0.05, 0.01). There were no adverse effects in both groups. Conclusion Shenfukang Capsule combined with Benazepril Tablets has a definite effect on reducing urine protein, RBC, Scr, and SUN than those in the treatment of Benazepril Tablets, without drug-related adverse reaction, which is worth clinical promotion.